Fig. 1From: Developing the latest framework to measure and incentivise pharmaceutical industry contributions to health research and developmentThe 2016 Access to Medicine Index found that the 20 companies measured had 420 projects in development targeting the needs of people in low- and middle-income countries (LMICs). Of these, 36% of projects (151/420) targeted a research and development (R&D) priority and 30% (126/420) had access plans in place, two-thirds (67% or 85/126) of which also targeted an R&D priority. To drive the industry further to ensure populations in LMICs gain rapid access to the most-needed products, the 2018 Index will deepen analysis on both criteria [3]Back to article page